RT Journal Article
SR Electronic
T1 Another step toward final call on Remdesivir efficacy as a treatment for hospitalized COVID-19 patients: a multicenter open-label trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.13.21261992
DO 10.1101/2021.08.13.21261992
A1 Hosseini, Hamed
A1 Sadeghi, Anahita
A1 Tabarsi, Payam
A1 Etemadimanesh, Azin
A1 Darazam, Ilad Alavi
A1 Aghdami, Nasser
A1 Kalantari, Saeed
A1 Hasibi, Mehrdad
A1 Hadadi, Azar
A1 Babamahmoodi, Farhang
A1 Momen-Heravi, Mansooreh
A1 Hormati, Ahmad
A1 Panahi, Yunes
A1 Khodashahi, Rozita
A1 Salehi, Mohammadreza
YR 2021
UL http://medrxiv.org/content/early/2021/08/13/2021.08.13.21261992.abstract
AB Introduction After emerging the global pandemic of SARS-CoV2 some preliminary studies demonstrated the efficacy of antiviral treatments. But shortly thereafter, inconsistencies in the results of further clinical trials raised doubts on the efficacy of these agents. In this study, we aimed to evaluate the effect of Remdesivir on hospitalized COVID-19 patients’ outcomes.Material and methods This study was an open-label, single-armed, clinical trial on hospitalized patients diagnosed with COVID-19 who had progressive respiratory symptoms despite receiving standard care. All patients received Remdesivir and their characteristics, outcomes, time of treatment initiation, and respiratory support stages during hospitalization were registered and followed up for 14 days.Results 145 patients with the mean age of 52.89 ± 1.12 years enrolled in this study, 38 (26.2%) died at the end of 14 days period. The mean time interval from the onset of the symptoms to antiviral treatment was 10.63±0.56 days. Thirty deceased patients (78.9%) were men, showing 2.8 times higher mortality chance compared to women (ORadj=2.77; 95%CI=1.08-7.09). The type of respiratory support on the first day of treatment initiation showed a significantly lower mortality chance in patients receiving O2 only than those who needed non-invasive and/or mechanical ventilation (ORadj=3.91; 95%CI=1.64-9.32). The start time (early vs late administration) and duration (less or more than 7 days) of antiviral treatment had no statistically significant association with mortality or ventilation escalation among the patients (p-value > 0.05).Conclusion In this study, we showed that Remdesivir probably is not effective on the outcome of hospitalized COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIRCT20200404046937N5Clinical Protocols https://www.irct.ir/trial/51178 Funding StatementThis study has been funded and supported by Tehran University of Medical Sciences (TUMS); Grant no. 99-1-97-47143.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval of this study was given by the ethics committee of Ahvaz University of Medical Sciences, Ahvaz, Khouzestan, Iran (Date of approval: 2020-09-22, ethics committee reference number of approval: IR.AJUMS.REC.1399.407)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available by request contacting the corresponding author